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Economics

Does Domestic Intellectual Property Right
Strength Affect Pharmaceutical Innovation?
Jacob (Jay) Kaplan
Mentor: Maria Canon
Intellectual Property Rights have been a contentious issue for the past few decades. The
conventional reasoning for the legal basis of patents is that it is worthwhile to grant an
inventor monopoly rights for a certain innovation that can be easily mimicked, thus
guaranteeing the inventor the fruits of her labor. The economic basis for patents is that
if an inventor or firm knows that they cannot be granted a patent for a potential
invention, then they will not be able to profit and thus there will be no incentive to
innovate. While granting a monopoly may spur innovation in certain cases, monopoly
pricing undoubtedly lowers consumer welfare. In addition, while the idea that patents
spurring innovation seems logical in most industries, economic research has not
strongly supported this argument. The question I address in this paper is whether
domestic intellectual property right strength is of importance specifically for
pharmaceutical innovation. I use pharmaceutical research and development
expenditure as a proxy for innovation to run panel regressions on 23 OECD nations. I
do comparison regressions between pharmaceutical R&D and total R&D to see if patent
strength is of more importance to the pharmaceutical industry. I use two indexes of
patent strength as independent variables, one for general patent strength and one
specifically for the pharmaceutical sector. I find that for pharmaceutical patent strength,
higher levels lead to an increase in innovation, with a positive marginal effect only
occurring at relatively high levels of patent strength. In the comparison regressions
using total R&D, I find that at lower levels increasing intellectual property strength
increases innovation up to a certain point, and that for most developed countries the
optimal patent strength has already been reached.

Spring 2017 WUSHTA

57

